Home · Healthcare M&A · Sell a Physical Therapy Practice in NJ

PT M&A Specialist Broker · NJ · NY · CT

Sell a Physical Therapy Practice in NJ

Nexus Bridge is the only NJ business brokerage dedicated to outpatient physical therapy M&A — connecting NJ PT practice owners with the active PE-backed buyers consolidating the tri-state in 2026. We handle the practices the national investment banks don't (single-site to 10-clinic groups, $300K–$5M EBITDA range) and bring senior-level engagement to every deal. $0 upfront. Success-only commission. Free 30-minute confidential conversation.

NJ PT M&A landscape, May 2026: Active PE acquirers include Upstream Rehabilitation, Professional PT (60+ NJ clinics), JAG-ONE (100+ NJ/NY/PA clinics, acquired Monmouth Rehab Dec 2024), SportsMed PT (54 NJ/CT clinics, Hildred Capital-backed), Ivy Rehab (36+ NJ locations + Theraplay pediatric), Athletico, USPH (NYU Langone alliance Feb 2026), Confluent/CORA. Tri-state PT is one of the most actively consolidated healthcare segments heading into 2026.

2026 NJ physical therapy valuation multiples

NJ PT practice valuations span a wide range — from 2.5× EBITDA for owner-dependent solo practices to 9×+ EBITDA for platform-eligible multi-site groups. The single biggest controllable multiple driver is owner dependency: if the owner-PT generates more than 25% of practice revenue, valuations get capped regardless of other factors. Lower owner dependency, stronger commercial payer mix, and clean Stark/AKS structure are the levers that meaningfully move the multiple.

Practice TypeEBITDA MultipleKey Driver
Single-site, owner-dependent (>50% revenue from owner-PT)2.5×–3.5×Owner dependency caps valuation
Single-site, low owner dependency, $300K–$750K EBITDA3.5×–5.0×Strong commercial payer mix lifts upper range
Multi-site (2–4 clinics)4.5×–6.5×Regional density premium begins
Multi-site (5–10 clinics)5.5×–8.0×Platform-eligible for PE buyers
Large platform (10+ sites, $5M+ EBITDA)9×–15×Add-on arbitrage drives premium
Sports / Orthopedic PT specialty5.5×–8.5×Commercial-heavy book and ortho referral lock-in
Pediatric PT5×–8×Specialty premium (Ivy/Theraplay consolidation)
Hand therapy (CHT)5×–7.5×Strategic interest from Confluent and Athletico
Pelvic floor PT5×–7.5×Cash-pay premium, $150–$200/session pricing
Neuro / specialty rehab4.5×–7×Higher per-visit revenue, smaller buyer universe
Cash-pay / boutique PT4×–6.5×Quality-of-earnings premium; scale-capped
PT integrated with orthopedic practice5×–8× standaloneStark/IOAS structure must be cleaned pre-sale
PT integrated with chiropractic3×–5×Referral concentration and credentialing complexity discount

Five-year average across all NJ PT practice transactions: ~3.6× EBITDA. Industry-wide range 2.5×–8× for single-site to mid-market practices; 9×–15× EBITDA for platforms with $5M+ EBITDA and continuing management.

Active PE buyers acquiring NJ PT practices

The tri-state is one of the most consolidated PT markets in the United States. Ten platform companies operate ~60% of all PE-affiliated PT locations nationally; New Jersey is firmly on that trajectory. The active 2026 acquirers:

Upstream Rehabilitation

Revelstoke Capital Partners-backed. 1,000+ clinics across 28 states post-Results Physiotherapy merger February 2025. Largest pure-play outpatient PT operator in the U.S. Selective NJ/NY presence; actively pursuing single-site and multi-site outpatient PT plus de novo development.

Professional Physical Therapy (ProPT)

Thomas H. Lee Partners-backed. 200+ clinics across five states — the Northeast's largest independent footprint. 60+ NJ locations across Bergen, Camden, Essex, Hudson, Mercer, Middlesex, Monmouth, Morris, Passaic, Somerset, Sussex, and Union counties. Plus NYC (Manhattan, Brooklyn, Queens, Bronx), Long Island, Westchester, and Connecticut. Generally regarded as preserving clinical autonomy more than larger national chains.

JAG-ONE Physical Therapy

Currently independent (Pamlico Capital exited 2022 — likely new sponsor process in progress). 100+ clinics across NJ, NY, and PA. Dominant NJ + NYC metro footprint formed by the 2018 merger of JAG and One on One PT. Recent NJ activity: acquired Monmouth Rehab Professionals (Manalapan, Jackson, South Amboy) December 2024. Strong sports/orthopedic PT focus.

SportsMed Physical Therapy

Hildred Capital Management-backed since 2018. 54 clinics across NJ and CT as of March 2026 — up from 7 in 2018. Pure NJ/CT footprint. Recent 2025–26 NJ acquisitions: Mendham PT (Morris County), Ridgewood, WeCare Medical PT (Maplewood); opened Emerson (Pascack Valley/Bergen) February 2026. The most active NJ-specific PT consolidator in 2026.

Ivy Rehab

Waud Capital Partners (continuation fund with Morgan Stanley PE Secondaries, October 2022). 700+ clinics nationally including 36+ NJ locations. Operates Theraplay (31 pediatric clinics across DE/NJ/PA/VA, acquired 2022) and Treehouse Pediatric Therapy (acquired September 2025) — making Ivy the largest U.S. outpatient pediatric rehab platform. Acquired DiSabatino PT (Sewell, NJ).

Athletico Physical Therapy

BDT Capital / Wind Point Partners-backed. 900+ clinics post-Pivot Health Solutions acquisition (including Accelerated, ProRehab, Newsome brands). Strong Eastern U.S. presence via the Pivot deal. Acquiring NJ practices selectively.

U.S. Physical Therapy (USPH)

Publicly traded on NYSE: USPH. 700+ clinics nationally. Major February 2026 NY development: 10-year strategic alliance announced with NYU Langone Health — USPH subsidiary Metro Physical & Aquatic Therapy's 60 outpatient clinics in Long Island + NYC metro integrating into NYU Langone's clinical services network through year-end 2026. USPH uses a partnership-equity model where sellers retain 20–50% ownership — a meaningfully different structure from the larger PE platforms.

Confluent Health / CORA

Partners Group-backed (Confluent); H.I.G. Capital-backed (CORA Physical Therapy). Confluent operates 820+ sites including Commonwealth Hand & PT specialty acquisition. CORA acquired One To One PT & Aquatics January 2025. Limited direct NJ/NY presence to date but actively pursuing Northeast expansion. Partners Group shelved a Confluent stake sale process in late 2024 — signals selective seller market for sub-platform PE assets.

PT Solutions, FYZICAL, BenchMark

PT Solutions (Lindsay Goldberg-backed, 3,000+ employees, Atlanta HQ) acquired OrthoCarolina's PT business in 2025; limited Northeast presence to date. FYZICAL Therapy & Balance Centers (600+ clinics) operates a franchise model rather than PE consolidation; limited acquisition activity. BenchMark is now subsumed under the Upstream platform.

Distressed: ATI Physical Therapy — NYSE delisted December 3, 2024 after a $54M net loss; trading on OTC Pink; taken private at $2.85/share August 2025 by debtholders Knighthead Capital + Marathon Asset Management. ATI reduced from peak footprint to 878 locations during "footprint optimization." Not a likely active acquirer in NJ/NY/CT in 2026. ATI's collapse made therapist attrition the dominant cautionary tale of the PT M&A space and elevated the importance of staff retention diligence.
The "tier 2" NJ PT market — independents with 2–6 clinics and $500K–$2M EBITDA — is currently the sweetest spot for sellers because it sits below the radar of national platforms (who target larger add-ons) but well above the threshold for serious PE add-on interest. Premium NJ PT auctions in this segment routinely produce 4–6 competing LOIs.

Key value drivers for NJ PT practice valuation

Multiple-expanding factors (in order of impact):

NJ and NY regulatory framework for PT practice sales

New Jersey

NJ PT practices are regulated by the NJ State Board of Physical Therapy Examiners (Division of Consumer Affairs) under N.J.S.A. 45:9-37.27 et seq. Critical point for PE M&A: only a natural person can be licensed as a PT in NJ — but the Board has confirmed that PTs may be employed by a non-licensee-owned corporation (including PE-backed entities), provided each PT maintains professional independence over clinical decisions, billing, and fee schedules. This permits the standard MSO structure used by every PE platform.

Practice structure norm: PCs or LLCs at the clinical level; PE platforms typically acquire the non-clinical management services entity (MSO) and contract for clinical services with a friendly-PC owned by NJ-licensed PT(s). Address and employment changes must be reported to the Board within 30 days. NJ has had direct access for PT since 2003 (P.L. 2003 c.18) — no physician referral required for most cases. Exception: PIP (auto injury) cases require referral from MD/DC/DPM. PT must refer out if no progress in 30 days or if condition is outside scope, and must notify the patient's PCP of plan of care within 30 days.

New York

NY PT is regulated by the NY State Education Department / Office of the Professions (NYSED OP) under Education Law Article 136 — not the Department of Health. This is a critical distinction that PE buyers and out-of-state brokers often miss.

NY enforces strict Corporate Practice of the Professions doctrine: PTs must operate via PLLC, PC, or DPC. Physicians are explicitly prohibited from co-owning a PT PC or PLLC. A physician may employ a PT, but a physician and PT cannot be co-owners. This matters when an orthopedic group wants to acquire or jointly own a PT entity in NY. Multi-profession PLLCs are allowed if every covered profession is represented by a licensed member; PCs are single-profession only. The MSO structure is the standard PE workaround: non-clinical management entity (any owner) + clinical PC owned by NY-licensed PT.

Article 28 (NY DOH-licensed Diagnostic & Treatment Centers) generally does not apply to standalone office-based PT practices. Hospital-affiliated outpatient PT or freestanding D&TCs offering PT alongside other services may fall under Article 28 — adds significant CON/licensing complexity. NY direct access is limited (10 visits or 30 days, whichever comes first, then referral required, with PT having 3+ years of experience).

Federal

2026 PT deal structure norms

Deal Component2026 Norm
Cash-at-close70–85% for sub-platform deals; 60–80% for larger deals with meaningful rollover
Rollover equityMinimum 10%, commonly 15–20%, up to 30% (USPH partnership model can go 50%+). Rolled equity participates in the platform's "second exit" 4–7 years later.
Earnouts10–25% of total consideration, typically 2–3 year measurement, tied to EBITDA growth or visit volume targets
Owner-PT post-close commitment2–5 year employment agreements standard. Many PE platforms require selling owner to remain clinically active for at least 24 months to preserve referral relationships.
Owner-PT post-close compensationMarket-rate clinical salary + bonus + platform equity. Net compensation drop of 20–40% from "all the cash flow" pre-sale is normal — offset by cash-at-close and rollover equity upside.
Real estateUsually handled separately. Sale-leaseback to third-party REIT or owner-retained landlord with 7–10 year triple-net lease at fair market rent is standard. PE buyers don't want real estate on the platform balance sheet.
Non-compete2–5 years; 5 years enforceable in NJ and NY under sale-of-business exception. Geographic scope usually 10–25 miles from clinics.
Working capital pegCash-free / debt-free standard. Peg set at trailing 12-month average normalized net working capital. PT-specific: A/R aging (60+ day A/R discounted in peg), unbilled visits, prepaid lease deposits.
Escrow / R&W holdback8–12% of purchase price for 12–24 months. R&W insurance increasingly common over $10M deals.
Quality of Earnings (QoE)Buyer-paid and standard above ~$2M EBITDA. Sellers should commission sell-side QoE before going to market. See QoE Guide.

The 2026 PT market headwinds and tailwinds

Medicare fee schedule pressure

The CY2026 Medicare Physician Fee Schedule final rule yields a net ~1% revenue decline for most PT practices despite a 3.26% conversion factor increase — because of permanent 2.5% efficiency adjustments to non-time-based codes including evaluation codes 97161–97164. Cumulative real-terms PT reimbursement is down ~14% since 2020. This is pushing valuation premiums toward practices with low Medicare exposure.

Cash-pay growth

Direct-pay / cash-based PT has been one of the fastest-growing PT segments. Cash rates of $95–$200/session (with pelvic floor at the high end) deliver Medicare-equivalent revenue without admin burden. Buyers now pay a quality-of-earnings premium for cash-pay-heavy books — though absolute valuations remain capped by the smaller scale of most cash practices.

Strategic alliance / hospital JV trend

The February 2026 USPH–NYU Langone Health alliance is the new template — selling practices into a 10-year clinical services alliance with a major health system at 20–50% retained ownership. Expect this model to expand to Mount Sinai, Atlantic Health, RWJBarnabas Health, and Hackensack Meridian through 2027.

Therapist retention as deal currency

Post-ATI, therapist retention is the dominant deal-execution risk. Detailed retention plans, stay bonuses ($5K–$25K per key PT vesting over 2 years), and minimum-percentage closing conditions on clinical staff signing offer letters (typically 75–85% of FTE-equivalent PTs) are now standard buyer requirements.

Frequently asked questions

What multiple does a NJ physical therapy practice sell for in 2026?

NJ PT practices typically sell at 3×–8× EBITDA depending on size, owner dependency, and payer mix. Single-site owner-dependent practices: 2.5×–3.5×. Single-site with low owner dependency: 3.5×–5×. Multi-site (2–4 clinics): 4.5×–6.5×. Multi-site (5–10 clinics): 5.5×–8×. Large platforms ($5M+ EBITDA, 10+ sites): 9×–15×. Sports/ortho specialty: 5.5×–8.5×. Pediatric: 5×–8×. The single biggest multiple driver is owner dependency — if the owner-PT generates more than 25% of revenue, valuations get capped regardless of other factors.

Which PE-backed PT platforms are acquiring NJ practices in 2026?

Upstream Rehabilitation (Revelstoke), Professional Physical Therapy (Thomas H. Lee Partners, 60+ NJ clinics), JAG-ONE Physical Therapy (100+ NJ/NY/PA), SportsMed PT (Hildred Capital, 54 NJ/CT clinics), Ivy Rehab (Waud Capital, 36+ NJ + pediatric platform), Athletico (BDT Capital), USPH (NYU Langone alliance Feb 2026), Confluent Health/CORA (Partners Group/HIG). ATI Physical Therapy went private at $2.85/share in August 2025 and is not a likely active acquirer.

How long does a NJ PT practice sale take?

Clean mid-market NJ PT practice sales typically take 6–9 months from engagement to funded close. Multi-site portfolios take 9–12 months. NY practices add 30–60 days for multi-payer credentialing transitions. Practices with QoE issues, payer mix complexity, or referral concentration concerns extend to 10–14 months. Owner-PT typically commits to 2–3 years post-close clinical practice continuity; 3–5 year employment agreements common for sellers under 60.

What's the typical deal structure?

70–85% cash at close. 10–30% rollover equity (USPH partnership model can go up to 50%). 10–25% earnout tied to 2–3 year EBITDA or visit volume targets. Owner-PT post-close commitment 2–5 years at market-rate clinical salary + bonus + platform equity. Real estate handled separately via sale-leaseback. Non-compete 2–5 years within 10–25 miles. Working capital peg on cash-free/debt-free basis. 8–12% escrow holdback for 12–24 months.

Does Stark Law affect my PT practice sale?

Yes — PT is a designated health service (DHS) under Stark. If your practice has any financial relationship with referring physicians (especially orthopedic surgeons referring Medicare patients), the structure must qualify under a Stark exception — most commonly the In-Office Ancillary Services (IOAS) exception for group practices. Stark is strict liability and PE buyers diligence this aggressively. We pre-screen Stark and AKS issues before going to market through specialty healthcare M&A counsel.

Will my staff PTs stay through the transition?

Therapist retention is the #1 concern after ATI's collapse made therapist attrition the dominant cautionary tale. PE buyers now routinely require detailed retention plans, stay bonuses ($5K–$25K per key PT vesting over 2 years), and conditioning closing on a minimum percentage of clinical staff signing offer letters (typically 75–85% of FTE-equivalent PTs). PE platforms vary widely in clinical model preservation — ProPT, JAG-ONE, and SportsMed are generally regarded as preserving clinical autonomy more than larger national chains.

Does Nexus Bridge charge upfront fees for PT practice sales?

No. Success-only commission. You pay nothing until your practice sells. Standard sliding scale: 10% on first $1M, 8% on $1M–$5M, sliding scale above. Sell-side QoE coordination, healthcare M&A counsel introduction, and Stark/AKS pre-screen included as part of the engagement at no additional cost.

How a Nexus Bridge PT practice engagement runs

  1. Free 30-minute confidential conversation. Discuss your practice, timeline, and target valuation. $0, no obligation.
  2. Free evidence-based valuation. NJ/NY/CT comparable transaction analysis from real 2026 PT M&A data. Delivered in writing within 7 days.
  3. Engagement letter signing. $0 upfront retainer, success-only commission. 12-month exclusivity, 12-month named-buyer tail.
  4. Sell-side Quality of Earnings preparation. Coordinated with healthcare-experienced CPA firm (Withum, Citrin Cooperman, BDO Healthcare, etc.) to defend normalized EBITDA before going to market.
  5. Stark / AKS pre-screen. Healthcare M&A counsel reviews any orthopedic referral relationships, IOAS arrangements, and physician compensation to clean up structural issues pre-LOI.
  6. CIM preparation. Confidential Information Memorandum tailored to PE-buyer expectations: visit volume trends, payer mix breakdown, therapist FTE roster with tenure, EMR system, lease portfolio, referral source distribution, sub-specialty mix.
  7. Targeted buyer outreach. Active PE PT platforms (Upstream, ProPT, JAG-ONE, SportsMed, Ivy Rehab, Athletico, USPH, Confluent/CORA) plus strategic acquirers and hospital-system JVs.
  8. Multi-LOI negotiation. Comparison framework on cash-at-close, rollover percentage, earnout structure, employment terms, real estate handling, and platform fit.
  9. Diligence coordination. QoE, legal, regulatory (Stark/AKS), payer-credentialing, EMR data export, therapist retention plan, real estate handling — all coordinated against the closing critical path.
  10. CMS PECOS CHOW transition. 60–90 day Medicare re-enrollment managed in parallel with state Medicaid and commercial payer credentialing.
  11. Close and post-close transition. Typically 6–9 months from listing to funded close for clean mid-market deals.

Free PT practice valuation

If you own a NJ, NY, or CT physical therapy practice and are considering a sale in the next 6–36 months, schedule a free confidential 30-minute conversation. We'll review your practice profile, give you a realistic 2026 valuation range, and tell you which PE platforms fit your specific situation. $0 upfront. Success-only commission. No obligation. Response within one business day.

Related: Healthcare M&A NJ Guide · Sell an Orthopedic Practice · Sell a Medical Practice · Quality of Earnings Guide · Healthcare M&A Glossary · Medical Practice Valuation Calculator

Free & Confidential

Get a Real Valuation for Your NJ Physical Therapy Practice

No obligation. No upfront fee. We reply within 1 business day.

Fully confidential. We never contact your employees, patients, or referral sources without your permission.